Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection.

IF 3.6 3区 医学 Q2 ONCOLOGY
American journal of cancer research Pub Date : 2025-02-15 eCollection Date: 2025-01-01 DOI:10.62347/KSLN5850
Chih-Jan Ko, Hung-Yu Lin, Pei-Min Hsieh, Wen-Lung Wang, Szu-Ying Chen, Li-Wei Chou, Yaw-Sen Chen, Yu-Wei Huang, Wen-Chao Ho, Chih-Wen Lin
{"title":"Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection.","authors":"Chih-Jan Ko, Hung-Yu Lin, Pei-Min Hsieh, Wen-Lung Wang, Szu-Ying Chen, Li-Wei Chou, Yaw-Sen Chen, Yu-Wei Huang, Wen-Chao Ho, Chih-Wen Lin","doi":"10.62347/KSLN5850","DOIUrl":null,"url":null,"abstract":"<p><p>The term \"metabolic dysfunction-associated steatotic liver disease\" (MASLD) was introduced to replace the term \"nonalcoholic fatty liver disease\". The prevalence of MASLD is increasing worldwide. The prevalence of concomitant MASLD and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is also increasing. This study explored the effect of the coexistence of MASLD and HBV on clinicopathological features and long-term clinical prognoses in patients with MASLD-related and/or HBV-related HCC after curative hepatectomy. The study retrospectively collected the data of 653 patients with HCC who had undergone curative hepatectomy between 2011 and 2022. We assessed the association of histologically confirmed MASLD with HCC recurrence and mortality. Of 653 patients, 320 (49.0%), 103 (15.8%), and 230 (35.2%) had concomitant MASLD and HBV, MASLD only, and HBV only, respectively. The median follow-up period was 5.1 years. Patients with concomitant MASLD and HBV were at a significantly increased risk of HCC recurrence (<i>P</i> = 0.013 and <i>P</i> = 0.041) and mortality (<i>P</i> = 0.044 and <i>P</i> = 0.026) than those with MASLD or HBV alone. In multivariable analyses, concomitant MASLD and HBV, male sex, body mass index < 23, absence of antiviral therapy, and tumor size ≥ 5 cm were significantly associated with increased HCC recurrence. Concomitant MASLD and HBV, male sex, type 2 diabetes mellitus, serum aspartate aminotransferase ≥ 40 U/L, tumor size ≥ 5 cm, tumor cell differentiation II-III, microvascular invasion, lymph node invasion, and tumor recurrence were significantly associated with increased mortality. In conclusion, patients with concomitant MASLD and HBV are at a significantly greater risk of HCC recurrence and mortality after curative hepatectomy than those with MASLD or HBV alone.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"737-748"},"PeriodicalIF":3.6000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897618/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/KSLN5850","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The term "metabolic dysfunction-associated steatotic liver disease" (MASLD) was introduced to replace the term "nonalcoholic fatty liver disease". The prevalence of MASLD is increasing worldwide. The prevalence of concomitant MASLD and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is also increasing. This study explored the effect of the coexistence of MASLD and HBV on clinicopathological features and long-term clinical prognoses in patients with MASLD-related and/or HBV-related HCC after curative hepatectomy. The study retrospectively collected the data of 653 patients with HCC who had undergone curative hepatectomy between 2011 and 2022. We assessed the association of histologically confirmed MASLD with HCC recurrence and mortality. Of 653 patients, 320 (49.0%), 103 (15.8%), and 230 (35.2%) had concomitant MASLD and HBV, MASLD only, and HBV only, respectively. The median follow-up period was 5.1 years. Patients with concomitant MASLD and HBV were at a significantly increased risk of HCC recurrence (P = 0.013 and P = 0.041) and mortality (P = 0.044 and P = 0.026) than those with MASLD or HBV alone. In multivariable analyses, concomitant MASLD and HBV, male sex, body mass index < 23, absence of antiviral therapy, and tumor size ≥ 5 cm were significantly associated with increased HCC recurrence. Concomitant MASLD and HBV, male sex, type 2 diabetes mellitus, serum aspartate aminotransferase ≥ 40 U/L, tumor size ≥ 5 cm, tumor cell differentiation II-III, microvascular invasion, lymph node invasion, and tumor recurrence were significantly associated with increased mortality. In conclusion, patients with concomitant MASLD and HBV are at a significantly greater risk of HCC recurrence and mortality after curative hepatectomy than those with MASLD or HBV alone.

肝癌根治性切除后伴发MASLD和乙型肝炎病毒与临床预后的关系
引入术语“代谢功能障碍相关脂肪变性肝病”(MASLD)来取代术语“非酒精性脂肪性肝病”。MASLD的患病率在世界范围内呈上升趋势。MASLD和乙型肝炎病毒(HBV)相关肝细胞癌(HCC)合并的患病率也在增加。本研究探讨MASLD和HBV共存对治愈性肝切除术后MASLD相关和/或HBV相关HCC患者临床病理特征和长期临床预后的影响。该研究回顾性收集了2011年至2022年间接受根治性肝切除术的653例HCC患者的数据。我们评估了组织学证实的MASLD与HCC复发和死亡率的关系。653例患者中,分别有320例(49.0%)、103例(15.8%)和230例(35.2%)合并MASLD和HBV、单纯MASLD和单纯HBV。中位随访期为5.1年。合并MASLD和HBV的患者HCC复发风险(P = 0.013和P = 0.041)和死亡率(P = 0.044和P = 0.026)明显高于单纯合并MASLD或HBV的患者。在多变量分析中,MASLD和HBV合并、男性、体重指数< 23、缺乏抗病毒治疗和肿瘤大小≥5 cm与HCC复发增加显著相关。合并MASLD和HBV、男性、2型糖尿病、血清天冬氨酸转氨酶≥40 U/L、肿瘤大小≥5 cm、肿瘤细胞分化II-III、微血管侵袭、淋巴结侵袭、肿瘤复发与死亡率增加显著相关。总之,合并MASLD和HBV的患者在根治性肝切除术后HCC复发和死亡的风险明显高于单纯合并MASLD或HBV的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
3.80%
发文量
263
期刊介绍: The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信